Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could happen, but devices have taken longer than normal,so don't get discouraged if it does not happen on that day.
Neoprobe Completes Senior Debt and Preferred Stock Exchanges
Company's Balance Sheet Strengthened
DUBLIN, Ohio, Jun 22, 2010 (BUSINESS WIRE) -- --Lymphoseek NDA Filing on Target
for Later this Summer
--Conference Call Scheduled for Wednesday June 23rd at 9:00 AM EDT
Neoprobe Corporation (NEOP), a diversified developer of innovative biomedical
surgical oncology products, today announced that Platinum-Montaur Life Sciences,
LLC (Montaur) has agreed to exchange all $10 million of its outstanding 10%
senior secured convertible notes and $3 million perpetual convertible preferred
stock for a single new series of preferred stock convertible into common shares
of Neoprobe Corporation. This transaction significantly strengthens the Company's
balance sheet and positions Neoprobe for an eventual listing on a major national
stock exchange.
Under the terms of the transaction, Montaur's $7 million Series A Convertible
Secured Note (originally convertible into 17.1 million common shares), $3 million
Series B Convertible Note (originally convertible into 8.3 million shares) and
Series A Convertible Preferred Stock (originally convertible into 6 million
shares) will be exchanged for Series B Convertible Preferred Stock (the Series B
Preferred, convertible into a total of 32.7 million shares). As part of the
consideration for the conversion, Neoprobe will "prepay" interest and dividends
due through the original note maturity in December 2011 by agreeing to issue an
additional 1.3 million shares of common stock on the conversion of the new Series
B Preferred. The Series B Preferred is convertible at the option of Montaur but
carries no dividend and has no liquidation preference over the common stock. The
Series A Convertible Preferred Stock was convertible at the option of Montaur and
paid an 8% dividend until converted.
In addition, Neoprobe announced that a $1 million convertible note held by
Neoprobe's President and CEO, David C. Bupp, and members of his family is also
being exchanged for Series C Convertible Preferred Stock with terms comparable to
the Series B Preferred, thereby effectively retiring all of the outstanding debt
of the Company.
Michael Goldberg, M.D., Principal, Montaur Capital Partners, LLC and Portfolio
Manager of Montaur, said, "Neoprobe has been and continues to represent an
excellent investment opportunity for Montaur. Our conversion from a secured debt
position into an equity position is a tangible sign of our continuing belief in
Neoprobe, its product portfolio, its product pipeline and its management. We
believe this transaction will assist Neoprobe in its efforts to qualify for a
listing on one of the major exchanges, which will serve to attract additional
investor interest and support. Further, we are pleased with Neoprobe's efforts to
deliver on its product development initiatives including the successful
completion of Phase 3 clinical studies of Lymphoseek(R) and the preparation of a
high quality New Drug Application (NDA) submission for Lymphoseek, progress on
RIGS(R), a product we believe has blockbuster potential and the numerous other
steps being taken to enhance shareholder value. Our confidence in the Company and
its deep product pipeline supports our decision to relinquish our secured
position so that the Company's capital structure will no longer be an impediment
for attracting institutional investors. Although the Company's share price has
improved dramatically since we first invested, we believe there still remains a
significant gap between the current market value and our assessment of true
value."
David Bupp said, "Neoprobe is pleased to announce the completion of this
significant financial transaction reflecting the development and
commercialization milestones achieved by the Neoprobe team to date. Retirement of
all of Neoprobe's outstanding debt and its conversion into equity brings Neoprobe
closer to qualifying for a listing on a major national stock exchange and the
removal of the security interest in our assets provides the Company with valuable
financial flexibility. Our financial partnership with Montaur has allowed us to
complete the clinical development of Lymphoseek, to prepare for the filing of the
NDA and ultimately to commercialize Lymphoseek."
Concluding, Mr. Bupp said, "Based on the feedback from the European Medicines
Agency (EMEA) and discussions with FDA to date, Neoprobe has developed a
prospective Phase 3 study for our RIGS initiative to replicate the results of
previous Phase 3 studies to supplement the safety and efficacy portion of the
regulatory submissions to be made to the open RIGS Biologic License Application
(BLA). We are nearing completion of the initial biologic manufacturing
initiatives for the RIGS technology consistent with the most recent favorable
scientific advice assessment received from the EMEA and expect feedback on the
harmonization of the RIGS program from FDA in the coming months. Our strengthened
balance sheet resulting from the transactions we announced today will also be
helpful as we continue discussions with development partners for our RIGS
technology following feedback from FDA. In tomorrow's conference call, I will be
joined by Dr. Goldberg and we will provide an update on these commercialization
matters including the favorable completion of pre-NDA meetings on the clinical
and non-clinical components of the NDA submission package for Lymphoseek, which
is on track to be filed later this summer."
Lymphoseek is a proprietary radioactive tracing agent being developed for use in
connection with gamma detection devices in a surgical procedure known as
Intraoperative Lymphatic Mapping. A Phase 3 multi-center clinical trial for
Lymphoseek in patients with breast cancer or melanoma has been successfully
completed and a second Phase 3 clinical study to evaluate the efficacy of
Lymphoseek as a sentinel lymph node tracing agent in patients with head and neck
squamous cell carcinoma is underway. The RIGS system is a proprietary technology
that utilizes tumor specific radiolabeled antibodies that localize to disease
involved tissue and where the tissue is identified during the course of a
patient's cancer surgery.
Mr. Bupp and Dr. Goldberg will make brief comments regarding the transaction and
be available to respond to questions during a conference call scheduled for 9:00
AM ET, on Wednesday June 23, 2010.
Conference Call Information
--------------------------------------------------------------------------------------------------------
TO PARTICIPATE LIVE:TO LISTEN TO A REPLAY:
------------------------------------------- ------------------------------------------------------------
Date:June 23, 2010AJ
Time:9:00 AM ETvailable until:uly 7, 2010
Toll-free (U.S.) Dial in # : 877-407-8033Toll-free (U.S.) Dial in # :877-660-6853
International Dial in # :201-689-8033International Dial in # :201-612-7415
Replay Passcodes (both required for playback): 286
Account # :352757
Conference ID # :
---------------------------- ----------------------------------------------------------- ------------
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving
patient outcome by meeting the critical intraoperative diagnostic information
needs of physicians and therapeutic treatment needs of patients. Neoprobe
currently markets the neoprobe(R) GDS line of gamma detection systems that are
widely used by cancer surgeons. In addition, Neoprobe holds significant interests
in the development of related biomedical systems and radiopharmaceutical agents
including Lymphoseek(R) and RIGScan(TM) CR. Neoprobe's subsidiary, Cira
Biosciences, Inc., is also advancing a patient-specific cellular therapy
technology platform called ACT. Neoprobe's strategy is to deliver superior growth
and shareholder return by maximizing its strong position in gamma detection
technologies and diversifying into new, synergistic biomedical markets through
continued investment and selective acquisitions. http://www.neoprobe.com
Statements in this news release, which relate to other than strictly historical
facts, such as statements about the Company's plans and strategies, expectations
for future financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the Company's
products are forward-looking statements The words "believe," "expect,"
"anticipate," "estimate," "project," and similar expressions identify
forward-looking statements that speak only as of the date hereof. Investors are
cautioned that such statements involve risks and uncertainties that could cause
actual results to differ materially from historical or anticipated results due to
many factors including, but not limited to, the Company's continuing operating
losses, uncertainty of market acceptance of its products, reliance on third party
manufacturers, accumulated deficit, future capital needs, uncertainty of capital
funding, dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, risks of development
of new products, regulatory risks and other risks detailed in the Company's most
recent Annual Report on Form 10-K and other Securities and Exchange Commission
filings. The Company undertakes no obligation to publicly update or revise any
forward-looking statements.
SOURCE: Neoprobe Corporation
Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
Makovsky + Company
Gene Marbach, 212-508-9645
Copyright Business Wire 2010
POSC News..Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and
solutions company specializing in the field of Nuclear Cardiology, announces
the sales of four Attrius(TM) PET scanners to prominent cardiology practices
and orders six Attrius(TM) PET scanners from its joint venture, Neusoft
Positron Medical Systems for immediate delivery.
As a result of the Centers for Medicare & Medicaid Services (CMS) 2010
Medicare Physician Fee Schedule whereby reimbursement for cardiac PET increased
and reimbursement for SPECT decreased there has been a significant increase in
demand for cardiac PET imaging. When combining the economic and medical imaging
advantages of cardiac PET compounded with the continued shortage of Molybdenum,
the parent radioisotope used in SPECT imaging, this increase in the demand for
cardiac PET is a trend that is expected to continue.
Positron's cardiac optimized dedicated PET scanner the Attrius(TM) is the
right choice at the right time for cardiovascular practices. With recent sales,
Positron has met its six month projections and predicts greater demand moving
forward. Based on Positron's sales pipeline and in preparation of meeting the
next six month projections, the Company has place a purchase order for six
systems for their earliest delivery. Positron's organic growth targets sales of
17 PET systems for 2010, 50 PET systems for 2011 and 125 PET systems for 2012
and fully expects to meet these goals.
Patrick G. Rooney, Chief Executive Officer of Positron stated, "Positron has
always been a leader in cardiac PET and we continue to make progress that
further validates our position that PET is the future of nuclear cardiology.
Positron is ideally positioned with the Attrius(TM) as the only dedicated
cardiac PET offering available. This year has seen the emergence of cardiac PET
and Positron. Our objective is to meet the strong demand and be the full
solutions provider for cardiac PET adopters. Positron projects an increase in
sales every quarter for the foreseeable future and is prepared to deliver.
Positron's corporate focus is aggressive growth while staying on track to
deliver positive earnings within 18 months."
About Positron: Positron is a molecular imaging company focused on Nuclear
Cardiology. Positron utilizes its proprietary product line to provide unique
solutions to the Nuclear Medicine community ranging from imaging to
radiopharmaceutical distribution. Positron products include: the Attrius(TM), a
PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. More information about
Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not guarantees
of future performance and may involve known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or
achievements of Positron Corporation to be materially different from future
results, performance or achievements expressed or implied by such
forward-looking statements. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a variety of
factors, including, without limitation those set forth as "Risk Factors" in our
filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317)576-0183.
CONTACT: Positron Corporation
Patrick G. Rooney, (317)576-0183
SOURCE: Positron Corporation
Copyright Business Wire 2010
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=4aTZSs2zjjoj5I1V7sb6KA%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-21-10 0944ET
09:44 062110
Alert HEB - Huge Insider Buy
SOURCE: Form 4
ISSUER: HEMISPHERX BIOPHARMA INC
SYMBOL: HEB
FILER: STRAYER DAVID R
TITLE: Officer
DATE TRANSACTION SHARES PRICE VALUE
6/16/10 Purchase 230,586 $0.58 $132,587
OWNERSHIP: 281,832 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=GqSKOauBkXOlPNBU0dFC3w%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-18-10 1448ET
14:48 061810
Alert..HEB - Huge Insider Buy
SOURCE: Form 4
ISSUER: HEMISPHERX BIOPHARMA INC
SYMBOL: HEB
FILER: STRAYER DAVID R
TITLE: Officer
DATE TRANSACTION SHARES PRICE VALUE
6/16/10 Purchase 230,586 $0.58 $132,587
OWNERSHIP: 281,832 (Direct)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=GqSKOauBkXOlPNBU0dFC3w%3D%3D. You can use
this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-18-10 1448ET
14:48 061810
Price is down on low volume...nothing to worry about...News is coming on the partnership and the 2 shows.Everything aligning well.
Charts show way oversold.
SPPI News...Annual Meeting of Shareholders until July 1, 2010
-- Company Urges Shareholders of Record as of April 20, 2010 to Vote Their
Shares
IRVINE, Calif.--(BUSINESS WIRE)--June 18, 2010--
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that it has
adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time,
Thursday, July 1, 2010, which will be held at the Company's corporate office
located at 157 Technology Drive, Irvine, California, 92618. The Company's proxy
materials previously filed with the Securities and Exchange Commission on April
28, 2010, and first mailed to the Company's stockholders on or about May 17,
2010, and the proposal being submitted to a vote of the stockholders at the
Annual Meeting, as described in such proxy materials, remain unchanged.
The Annual Meeting was adjourned to provide the Company with additional time
to solicit proxies from its stockholders to establish the requisite quorum for
the conduct of business at the Annual Meeting. A majority of the aggregate of
the shares of the Company's common stock and preferred stock that were
outstanding as of April 20, 2010, the record date for the Annual Meeting, must
be present at the Annual Meeting, either in person or by proxy, to establish a
quorum. As of June 18, 2010, approximately 47% of those shares have been voted.
The Company encourages those stockholders that held shares of the Company's
common stock or preferred stock as of April 20, 2010 to vote their shares.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals is a commercial-stage biotechnology company with a
focus in oncology and hematology. The Company's strategy is comprised of
acquiring, developing and commercializing a broad and diverse pipeline of
late-stage clinical and commercial products. In addition to continuing to build
an efficient in-house clinical research organization with regulatory and data
management capabilities, the Company has established a commercial
infrastructure to market its drug portfolio. The Company markets two oncology
drugs, ZEVALIN(R) and FUSILEV(R) and has two drugs in late stage development,
apaziquone and belinostat, along with a diverse pipeline. The Company also
leverages the expertise of its worldwide partners to assist in the execution of
its strategy. For more information, please visit the Company's website at
www.sppirx.com.
Forward-looking statement -- This press release may contain forward-looking
statements regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could cause actual
results to differ materially. These statements include but are not limited to
statements that relate to our business and its future, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the expertise of
partners around the world to assist us in the execution of our strategy, and
any statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical fact.
Risks that could cause actual results to differ include the possibility that
our existing and new drug candidates, may not prove safe or effective, the
possibility that our existing and new drug candidates may not receive approval
from the FDA, and other regulatory agencies in a timely manner or at all, the
possibility that our existing and new drug candidates, if approved, may not be
more effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop additional
drug candidates may fail, our lack of revenues, our limited marketing
experience, our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in this press
release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.(R), ZEVALIN(R), and FUSILEV(R) are registered
trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE(TM) and the
Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals,
Inc.
POSC more news....Bracco Reports Cardiac PET Growth
INDIANAPOLIS, Jun 18, 2010 (BUSINESS WIRE) -- Positron Corporation (POSC), a
leader as a molecular imaging and solutions company specializing in the field of
Nuclear Cardiology, cites an article posted on AuntMinnie.com, the largest
community website for medical imaging professionals, relating to the growth in
cardiac PET.
Contrast agent developer Bracco Diagnostics said that the number of customers
using its CardioGen-82 cardiac PET myocardial perfusion imaging (MPI) tracer has
increased by 46% in comparison with June of 2009.
The Princeton, NJ-based vendor attributed the growth to increasing momentum for
cardiac PET, publication of key clinical data, improvements in PET
hardware/software technology and accessibility, and expanding society and
academic advocacy for MPI.
Joseph Oliverio, Chief Technology Officer of Positron states, "The Bracco release
further confirms our market growth prediction. We are seeing an unprecedented
request for proposals and look forward to meeting the increasing demand."
About Positron: Positron founded in 1983, is a molecular imaging company focused
on Nuclear Cardiology. Positron utilizes its proprietary product line to provide
unique solutions to the Nuclear Medicine community ranging from imaging systems
to radiopharmaceutical distribution. Positron products include: the Attrius(TM),
a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is
headquartered in Indianapolis, Indiana. More information about Positron is
available at http://www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements
are based on many assumptions and estimates and are not guarantees of future
performance and may involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
Positron Corporation
Joseph Oliverio, (317) 576-0183
Copyright Business Wire 2010
POSC Biomed News..
Positron seeing substantial accumulation. May pierce resistance levels.
Written by M.E.Garza
Thursday, 17 June 2010 14:32
Positron Corporation (OTCBB:POSC), a leader in molecular imaging and solutions specializing in the field of Nuclear Cardiology has just released a report over the news wires highlighting some of the company's key points and developments.
The stock has been seeing quite a bit of accumulation since shares broke the $.10 support level a few days ago and Thursday, shares closed up 11.6% at $.125. We believe the stock will climb higher pending announcements and long awaited official revelation of a key relationship or two with big-cap firms in the biotech imaging space. Those relationships and developments, as they are announced, may signal what investors have been waiting for: the validation and start of next level of commercialization and deployment activities surrounding the company's Molecular Imaging Devices and Radiopharmaceutical Products.
Here is a marked up technical analysis chart of the company:
Here is a synopsis of some of the key points which were announced today by the company:
Positron’s core focus is to leverage their unique technologies and competencies to offer an industry unique total customer solution which includes low cost molecular imaging devices and service, disease specific software, radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear Cardiology. Positron's strategy is to utilize all of its innovative equipment to maximize market share within the molecular imaging market.
Positron’s molecular imaging device segment includes the Attrius™, a Positron Emission Tomography (PET) imaging device that is the only cardiac optimized dedicated PET device in the world.
Positron’s Attrius™ PET scanner, with its robust software package, will help physicians provide a more accurate diagnosis for patients, the potential to reduce unnecessary downstream procedures and allow for higher reimbursement compared to SPECT. Positron also offers a Single Photon Emission Computed Tomography (SPECT) camera, the Pulse™, is one of the leading SPECT imaging devices in the industry with over 150 units sold.
Positron’s radiopharmaceutical segment includes the Nuclear Pharm-Assist® line of equipment, the world’s first robotic system for the distribution of radiopharmaceutical agents for PET and SPECT imaging devices. The Nuclear Pharm-Assist® automates the preparation and dispensing of radiopharmaceuticals and acts as a “virtual pharmacy” located on site at the nuclear pharmacy or physician’s office to dispense the radiopharmaceutical as a patient specific dose. The Nuclear Pharm-Assist® makes the distribution of the radiopharmaceutical economical, efficient and regulatory compliant.
The market at the present time is 7,000+ cardiac imaging opportunities that are all ideal candidates for the evolution of PET imaging and the direct distribution of radiopharmaceuticals.
Positron estimates the market for dedicated cardiac PET scanners in the United States to be above $3 billion in device sales over the next 5 years. According to Bio-Tech Systems, a research firm that covers the diagnostic imaging market, nuclear cardiology radiopharmaceutical sales of $1.29 billion in 2007 will increase to $2.10 billion by 2014. In a study conducted by Frost & Sullivan, the medical imaging consumables market is expected to grow at a compound annual rate of 14 percent, driven by an aging baby boomer population & increased life expectancy this rise is increasing more than twice as fast as the total population.
If you go to the top tool bar,click on hot and then drop down Breakout boards,we are still there at 30 and yesterday at 13
Natures Peak will also be at the 56th Summer Fancy Food Show
June 27-29, 2010 in New York. This is bigger than even the Kehe Holiday Show.
Congrats to FDA PLAYS...We are number 14 on the IHUB Break Out Boards!!!
Insider Trade Alert on NEOP
SOURCE: Form 4
ISSUER: NEOPROBE CORP
SYMBOL: NEOP
FILER: MILLER FRED B
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
6/16/10 Purchase 10,000 $1.56 $15,600
OWNERSHIP: 50,000 (Direct) 91,000 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=fK3OT%2BzzxHMGA2%2BJkQ4xgQ%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-17-10 1406ET
14:06 061710
Insider Trade Alert...NEOP
SOURCE: Form 4
ISSUER: NEOPROBE CORP
SYMBOL: NEOP
FILER: MILLER FRED B
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
6/16/10 Purchase 10,000 $1.56 $15,600
OWNERSHIP: 50,000 (Direct) 91,000 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=fK3OT%2BzzxHMGA2%2BJkQ4xgQ%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-17-10 1406ET
14:06 061710
Have a great day,KEI and thank you for all the input you have given this board.
POSC More News....Imagin Molecular Corporation Acquires an Investment Position in Positron
Corporation Currently Valued at $35 Million
CHICAGO, Jun 17, 2010 (BUSINESS WIRE) -- The Shareholders of Imagin Molecular
Corporation ("IMGM") have approved, through a consent of over 51% of shareholder
vote, certain transactions wherein IMGM completed the acquisition of 3,100,000
Class B Preferred Shares of Positron Corporation which shares are convertible on
a 1 for 100 basis into Positron common shares. This position marked to the
current market price for Positron Corporation common shares has a value of in
excess of $35 million. It is IMGM's intention to hold the Positron Class B
Preferred shares for investment purposes. The consideration for the exchange of
the Positron investment position is the issuance of 310,000,000 common shares of
IMGM to IMAGIN Diagnostic Centres, Inc. (IDC) a private Canadian company that is
in the PET scanning business in Canada and a historical owner of the 3,100,000
Class B preferred block equity position. IMGM simultaneously announces its intent
to build Cardiac Disease Reversal and Prevention Clinics across Canada and, after
initial success, across the USA and globally. The new subsidiary will be named
"Positron Cardiac CARE Clinics". These clinics will base its imaging technology
on Positron's Attrius(TM) dedicated cardiac PET scanners.
Currently IMGM holds approximately one Positron common share equivalent for each
IMGM common share outstanding. Positron preferred shares have been held by IMGM
since 2005. Upon completion of the exchange of Positron preferred shares for IMGM
common shares, IMGM will own the equivalent of 386,235,800 Positron common shares
and upon completion of this transaction IMGM will have 405,000,000 common shares
outstanding with no significant debt or preferred stock outstanding.
About Imagin Molecular Corporation:
Imagin Molecular Corporation (IMGM) is a company dedicated to socially
responsible issues. IMGM main areas of interest are focused on medical and
environmental. IMGM through its subsidiary Positron Cardiac CARE Clinics ("PCCC")
is planning to open Cardiac Disease Reversal Clinics across Canada and after
initial success across the USA and globally.
IMGM through a newly to-be-formed 51% owned subsidiary The Planet Green Bottle
Corporation has developed and is introducing globally through a subsidiary, the
world's first and only oxo-biodegradable PET (polyethylene terephthalate) plastic
bottle. The Planet Green oxo-biodegradable technology was developed by Wells
Plastics Ltd of the UK and is proprietary with patent pending trademarked by
Wells as Reverte.
Imagin Molecular Corporation strategy and focus in its medical segment is
dedicated to capitalizing on opportunities in positron emission tomography (PET)
directed toward the diagnosis of cancer, heart disease and neurological diseases.
PET is an advanced medical diagnostic imaging procedure used by physicians in the
detection of certain cancers, coronary disease and neurological disorders
including Alzheimer's disease. IMAGIN Molecular Corporation has a large strategic
equity block position in Positron Corporation. The Positron technology is
considered to be the gold standard for cardiac disease diagnosis.
About Planet Green Bottle Corporation
Planet Green Bottle Corporation ("PGBC") initiated with Wells Plastics Ltd. of
the UK, the development of a masterbatch additive which causes a PET plastic
bottle to become oxo-biodegradable in the environment. The Planet Green concept
is to promote its "The PLANET BOTTLE" logo as a brand enhancer wherein the
consumer will search for "The PLANET BOTTLE" logo on a brand owner's label as a
sign that the plastic bottles and packaging are eco-friendly and will
oxo-biodegrade over 10-20 years as opposed to perhaps over 1,000 years for
non-treated PET plastic. Planet Green markets its product to brand owners
globally. Planet Green is also working with governmental agencies around the
world in order to influence legislation mandating that all plastics be treated
with oxo-biodegradable additives as a step toward curtailing the pollution of the
Planet with Plastic. IMGM acquired the proprietary position and intellectual
property of PGBC of Canada in exchange for giving up a 49% interest in its
corporate venture to be also called PGBC, a Delaware-incorporated subsidiary.
SOURCE: Imagin Molecular Corporation
for Imagin Molecular Corporation
Patrick J. Rooney
Director of Corporate Development
416 941-9955
Copyright Business Wire 2010
BIEL Up-Listed...to OTCQB
http://www.otcmarkets.com/stock/BIEL/quote
BIEL Up-Listed to OTCQB
http://www.otcmarkets.com/stock/BIEL/quote
BIEL Update..Bioelectronics (BIEL) and YesDTC (YESD) Subject of Prestigious Newletter – BIEL Now Quoted as OTC
by Joe on June 17, 2010
Some great news for BioElectronics (BIEL) and my public company, YesDTC Holdings (YESD), this morning. BioMedReports has both companies featured on the cover page of is paid subscription service. They indicated that later today a press release will be issued to the public concerning their recommendation.
Additionally, it appears BioElectronics’ long journey to move from Pink Sheet trading to the OTC may be complete as BIEL shares get status changed to OTCQB the morning. I will verify later today, but it appears this means the shares are now fully OTCBB. Both BIEL and YESD are very excited about what we are seeing in the Japanese market. The recent product improvements will go a long way with the Japanese consumer who is typically highly discerning and quality conscious. Here is the copy of what was put out by the very prestigious BioMedReports newsletter. For full additional information about YesDTC (YESD), where I am the CEO, you can also read the shareholder letter we issued yesterday in a press release, and of course, there is a huge amount of information on BIEL here on the blog. Exciting times for both BIEL and YESD as we begin to target the Japanese market and as YESD rolls out marketing programs for several other products. Joe Noel
Medical Device Distributor Armed With Unique Products
Last year, one of the strongest stock price percentage gains was seen by a small medical device company called BioElectronics Corp., which trades on the pink sheets under the symbol BIEL . We wrote rather extensively about this company and many of our readers saw tremendous gains. The stock rose significantly on the hopes that the company’s pulsed electromagnetic frequency (PEMF) drug-free, anti-inflammatory device would receive FDA clearance. Despite multiple attempts, that clearance hasn’t been realized.
Even as late as yesterday, the company announced a revised strategy to gain clearance. Investors who like the technology have been looking at an alternative method for playing the huge revenue growth potential of the product and others like it.
Earlier this year, a startup called YesDTC Holdings, a fully reporting over the counter company trading under the symbol YESD, acquired the exclusive Japanese marketing rights for all of BioElectronics products. Like BIEL before it, this could turn into one of the most exciting and undervalued small-cap plays in the medical device related area of the market as we hear that the company has set its sights on acquiring many other brands and technologies which it can market directly to consumers around the globe. In the days ahead, we believe the company will announce more acquisitions and agreements which will affect both top and bottom line revenue growth and we are advising small-cap investors interested in the space to place the company on their watch list.
Earlier today, the companies issued a joint press release indicating that some significantly improve products and a revolutionary treatment for back pain when the first marketed into the Japanese market, via YesDTC. Profits in the back pain market could be substantial considering that the American Academy Of Orthopedic Surgeons says that there are more than 16 million office visits annually in the US alone relating to back pain. According to Duke University, more than $26 billion each year is consumed within the healthcare industry specifically relating to the back.
While marketing of the Allay menstrual pain product has been hampered in the U.S. due to lack of FDA clearance, entry into the Japanese market for this product should be relatively easy and highly profitable. This is a huge market with researchers estimating that between 60 to 70% of women suffer from pain during menstruation, with tens of millions of women experiencing pain so severe that they often call in sick to work or otherwise restrict their normal activities.
After looking closely at YesDTC, we think it is one of the best undiscovered medical device plays on the market today because it has the potential to align multiple commercial revenue streams while building a strong distribution base for several medical device and healthcare related products.
The BioElectronics product line is only the first of many that are likely to produce strong near-term revenue growth without the on-going expenses associated with development and regulatory clearance pipelines.
The company also has its sights set on a significantly improved personalized medical alarm technology that will allow two-way conversations from a pendant. Sources tell us that YesDTC is in the process of bringing the product to market in competition with industry leader Life Alert Emergency Response, Inc.- famous for its. “I’ve fallen and I can’t get up” television commercials. In addition, we are told that the company is also on the verge of acquiring an additional brand that is doing tens of millions of dollars in revenue already in the U.S. alone.
While the revenue growth possibilities for BioElectronics are still constrained due to their year-long battle with the FDA for marketing clearance, investors may want to look at this distributor YesDTC (YESD) as an alternative way to make a play for medical device profits.
We believe the other brands the company is getting ready to launch may offer a significant amount of upside revenue potential. In addition, we think you should be watching the stock over the short term as rumors are beginning to swirl that Japanese marketing clearances are close at hand. Should these events occur, the stock appreciation could be significant.
BIEL Update..Bioelectronics (BIEL) and YesDTC (YESD) Subject of Prestigious Newletter – BIEL Now Quoted as OTC
by Joe on June 17, 2010
Some great news for BioElectronics (BIEL) and my public company, YesDTC Holdings (YESD), this morning. BioMedReports has both companies featured on the cover page of is paid subscription service. They indicated that later today a press release will be issued to the public concerning their recommendation.
Additionally, it appears BioElectronics’ long journey to move from Pink Sheet trading to the OTC may be complete as BIEL shares get status changed to OTCQB the morning. I will verify later today, but it appears this means the shares are now fully OTCBB. Both BIEL and YESD are very excited about what we are seeing in the Japanese market. The recent product improvements will go a long way with the Japanese consumer who is typically highly discerning and quality conscious. Here is the copy of what was put out by the very prestigious BioMedReports newsletter. For full additional information about YesDTC (YESD), where I am the CEO, you can also read the shareholder letter we issued yesterday in a press release, and of course, there is a huge amount of information on BIEL here on the blog. Exciting times for both BIEL and YESD as we begin to target the Japanese market and as YESD rolls out marketing programs for several other products. Joe Noel
Medical Device Distributor Armed With Unique Products
Last year, one of the strongest stock price percentage gains was seen by a small medical device company called BioElectronics Corp., which trades on the pink sheets under the symbol BIEL . We wrote rather extensively about this company and many of our readers saw tremendous gains. The stock rose significantly on the hopes that the company’s pulsed electromagnetic frequency (PEMF) drug-free, anti-inflammatory device would receive FDA clearance. Despite multiple attempts, that clearance hasn’t been realized.
Even as late as yesterday, the company announced a revised strategy to gain clearance. Investors who like the technology have been looking at an alternative method for playing the huge revenue growth potential of the product and others like it.
Earlier this year, a startup called YesDTC Holdings, a fully reporting over the counter company trading under the symbol YESD, acquired the exclusive Japanese marketing rights for all of BioElectronics products. Like BIEL before it, this could turn into one of the most exciting and undervalued small-cap plays in the medical device related area of the market as we hear that the company has set its sights on acquiring many other brands and technologies which it can market directly to consumers around the globe. In the days ahead, we believe the company will announce more acquisitions and agreements which will affect both top and bottom line revenue growth and we are advising small-cap investors interested in the space to place the company on their watch list.
Earlier today, the companies issued a joint press release indicating that some significantly improve products and a revolutionary treatment for back pain when the first marketed into the Japanese market, via YesDTC. Profits in the back pain market could be substantial considering that the American Academy Of Orthopedic Surgeons says that there are more than 16 million office visits annually in the US alone relating to back pain. According to Duke University, more than $26 billion each year is consumed within the healthcare industry specifically relating to the back.
While marketing of the Allay menstrual pain product has been hampered in the U.S. due to lack of FDA clearance, entry into the Japanese market for this product should be relatively easy and highly profitable. This is a huge market with researchers estimating that between 60 to 70% of women suffer from pain during menstruation, with tens of millions of women experiencing pain so severe that they often call in sick to work or otherwise restrict their normal activities.
After looking closely at YesDTC, we think it is one of the best undiscovered medical device plays on the market today because it has the potential to align multiple commercial revenue streams while building a strong distribution base for several medical device and healthcare related products.
The BioElectronics product line is only the first of many that are likely to produce strong near-term revenue growth without the on-going expenses associated with development and regulatory clearance pipelines.
The company also has its sights set on a significantly improved personalized medical alarm technology that will allow two-way conversations from a pendant. Sources tell us that YesDTC is in the process of bringing the product to market in competition with industry leader Life Alert Emergency Response, Inc.- famous for its. “I’ve fallen and I can’t get up” television commercials. In addition, we are told that the company is also on the verge of acquiring an additional brand that is doing tens of millions of dollars in revenue already in the U.S. alone.
While the revenue growth possibilities for BioElectronics are still constrained due to their year-long battle with the FDA for marketing clearance, investors may want to look at this distributor YesDTC (YESD) as an alternative way to make a play for medical device profits.
We believe the other brands the company is getting ready to launch may offer a significant amount of upside revenue potential. In addition, we think you should be watching the stock over the short term as rumors are beginning to swirl that Japanese marketing clearances are close at hand. Should these events occur, the stock appreciation could be significant.
POSC News..Positron Key Points & Developments
INDIANAPOLIS, Jun 17, 2010 (BUSINESS WIRE) -- Positron Corporation (POSC), a
leader as a molecular imaging and solutions company specializing in the field of
Nuclear Cardiology states the Company's key points and developments.
Positron's core focus is to leverage their unique technologies and competencies
to offer an industry unique total customer solution which includes low cost
molecular imaging devices and service, disease specific software,
radiopharmaceutical distribution delivery systems, and imaging agents for Nuclear
Cardiology. Positron's strategy is to utilize all of its innovative equipment to
maximize market share within the molecular imaging market.
Positron operates through two segments: Molecular Imaging Devices and
Radiopharmaceutical Products.
Positron's molecular imaging device segment includes the Attrius(TM), a Positron
Emission Tomography (PET) imaging device that is the only cardiac optimized
dedicated PET device in the world. The Attrius(TM) PET scanner is the ideal
solution for Cardiologists looking to add new technology to their practice.
Positron's Attrius(TM) PET scanner, with its robust software package, will help
physicians provide a more accurate diagnosis for patients, the potential to
reduce unnecessary downstream procedures and allow for higher reimbursement
compared to SPECT. Positron also offers a Single Photon Emission Computed
Tomography (SPECT) camera, the Pulse(TM), is one of the leading SPECT imaging
devices in the industry with over 150 units sold.
Positron's radiopharmaceutical segment includes the Nuclear Pharm-Assist(R) line
of equipment, the world's first robotic system for the distribution of
radiopharmaceutical agents for PET and SPECT imaging devices. The Nuclear
Pharm-Assist(R) automates the preparation and dispensing of radiopharmaceuticals
and acts as a "virtual pharmacy" located on site at the nuclear pharmacy or
physician's office to dispense the radiopharmaceutical as a patient specific
dose. The Nuclear Pharm-Assist(R) makes the distribution of the
radiopharmaceutical economical, efficient and regulatory compliant. The Nuclear
Pharm-Assist(R) will change radiopharmaceutical distribution by placing the
dispensing of imaging agents back in the hands of the Cardiologist. This level of
control will increase patient throughput, advance patient safety through complete
dose customization, and lower costs by removing inefficiencies in the current
distribution model. The Nuclear Pharm-Assist(R) allows the clinician to comply
with the highest regulatory standards while increasing the quality of care. The
Nuclear Pharm-Assist(R) is focused on cardiology however it can also be utilized
for oncology.
The market at the present time is 7,000+ cardiac imaging opportunities that are
all ideal candidates for the evolution of PET imaging and the direct distribution
of radiopharmaceuticals. Positron estimates the market for dedicated cardiac PET
scanners in the United States to be above $3 billion in device sales over the
next 5 years. According to Bio-Tech Systems, a research firm that covers the
diagnostic imaging market, nuclear cardiology radiopharmaceutical sales of $1.29
billion in 2007 will increase to $2.10 billion by 2014. In a study conducted by
Frost & Sullivan, the medical imaging consumables market is expected to grow at a
compound annual rate of 14 percent, driven by an aging baby boomer population &
increased life expectancy this rise is increasing more than twice as fast as the
total population.
Positron's product line meets the needs for nuclear cardiology and directly
addresses the call for affordable health care at a time of intense scrutiny on
all costs associated with medicine. The marketplace has never been stronger for
cardiac PET and efficient radiopharmaceutical distribution and we see exponential
sales growth in the near future.
KEY POINTS & DEVELOPMENTS
PET IMAGING DEVICES
-- Positron's Attrius(TM) is the only FDA approved standalone dedicated cardiac
PET scanner on the market optimized for cardiology. All major PET manufacturers
have discontinued manufacturing of PET only systems, offering only PET/CT
instead. The addition of an expensive CT provides certain advantages for oncology
imaging applications however is not necessary for cardiac imaging procedures.
PET/CT has also been shown to have higher radiation exposure levels to patients
compared to dedicated PET. Positron intends to fill the market niche with its
Attrius(TM) Cardiac PET.
-- The Attrius(TM) includes a robust, cardiac specific, imaging software package
designed to ensure effortless interpretation for today's most challenging
clinical cases for nuclear cardiologists who value high quality PET imagery at an
affordable price. The system is designed to provide concurrent acquisition,
reconstruction, image processing and display, as well as other functions such as
data archiving, without interference.
-- Positron's Attrius(TM) named "Most Innovative Medical Device of 2010 Award" by
the industry leading research firm, Frost and Sullivan.
-- A twofold increase in reimbursement of cardiac PET applications by CMS in the
last 3 years, with a 25% increase in 2010 alone (while SPECT cardiac imaging
reimbursement has been decreased by 20%), which has greatly increased interest in
cardiac PET applications. These dramatic changes further validates that PET is
the future of nuclear cardiology and that there is an industry wide urgency in
the evolution to PET from SPECT.
-- CMS (Medicare) has approved PET as a first-line cardiac diagnostic test. The
medical imaging industry has regarded PET as the best imaging modality;
-- With recent increased reimbursement and challenging medical budgets, it
further validates PET as the most efficient, economical and provides the best
medicine choice for physicians. PET is the next SPECT which currently is 99% of
the cardiac imaging market. As PET replaces a large percentage of SPECT systems,
this would represent a total cardiac PET device market of approximately $3
billion dollars.
PHARMACEUTICALS
-- Positron's revolutionary "virtual pharmacy" solutions, Nuclear Pharm-Assist(R)
allows placing pharmaceutical dose delivery systems into nuclear pharmacy's
and/or the physician's offices and provides unprecedented "Unit Dose" flexibility
to imaging providers at the touch of a button, 24/7. The systems meets the
requirements of the United States Pharmacopeia Chapter 797 compounding
regulations as a compounding aseptic containment isolator (CACI) and provides the
ISO Class 5 environment necessary for USP-797 compliance as well as automating
the basic radiopharmaceutical compounding procedures. Most Nuclear medicine
facilities and nuclear pharmacies are underprepared and have to make considerable
investments to meet requirements of USP-797 which are in force since June 2008.
Nuclear Pharm-Assist(R) provides Automation, Shielding, Compliance, Patient
management, Costs & Margins.
-- Positron has an agreement with an industry leading partner for the development
and distribution of cardiac radiopharmaceuticals. This partnership represents
thousands of potential customers throughout the US and world. Each distributed
Nuclear Pharm-Assist(R) system represents approximately $250,000 in annual sales.
This pending rollout will be the beginning of Positron being a leader in
radiopharmaceutical distribution.
-- Radiopharmaceuticals, Sestimibi and Rubidium, are now available as a generic
pharmaceutical and are set to become commercially available with a number of
pharma companies. Lower cost and increased suppliers will help grow our segment
of the industry. Positron is working with the largest companies in this field.
-- A number of the largest radiopharmaceutical companies are developing single
dose cardiac PET imaging agents. This fact alone further validates that PET is
the most valuable first line cardiac imaging modality. New cardiac PET specific
radiopharmaceuticals will further increase the demand for Positron's Attrius(TM)
Cardiac PET system, the only new PET only device available today. Positron
patient studies demonstrate that the Attrius(TM) PET scanner meets the
performance requirements for all PET myocardial perfusion imaging tracers.
-- Positron has a number of patents and patents pending. Most recently has
received a patent on its Tech-Assist(TM), FDG injection shielding device.
-- Molybdenum (SPECT drug) shortages have increased the value if not necessity of
its model of drug distribution. This drug shortage awakens the industry to the
rationale and relevance of the Positron Nuclear Pharm-Assist(R) line.
Positron will explore additional strategic interests to the Company that advance
PET imaging systems and radiopharmaceutical distribution. Positron will continue
to evaluate all organic and strategic partnership opportunities and is prepared
to engage in more robust business development opportunities that meet its
objectives as being the leader in nuclear cardiology. These opportunities could
be in a variety of areas, such as partnerships with cardiologist practices,
radiopharmaceutical distribution, radiopharmaceutical manufacturing and
partnerships with companies that serve the molecular imaging industry. As
Positron executes its core focus and strategic interest areas, additional areas
may be pursued.
About Positron: Positron founded in 1983, is a molecular imaging company focused
on Nuclear Cardiology. Positron utilizes its proprietary product line to provide
unique solutions to the Nuclear Medicine community ranging from imaging systems
to radiopharmaceutical distribution. Positron products include: the Attrius(TM),
a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear
Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the
Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is
headquartered in Indianapolis, Indiana. More information about Positron is
available at http://www.positron.com.
Forward Looking Statements: Statements in this document contain certain
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements
are based on many assumptions and estimates and are not guarantees of future
performance and may involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements of
Positron Corporation to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. Our
actual results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with the Securities
and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
Positron Corporation
Patrick G. Rooney, (317) 576-0183
Copyright Business Wire 2010
CYTX News..Fat Grafts Shows Continued High Rates of Physician and Patient Satisfaction at
12 Months
Interim Data Presented at British Oncoplastic Surgery Meeting; Complete
12-Month Results Expected in Early 2011
SAN DIEGO--(BUSINESS WIRE)--June 17, 2010--
Interim results from a breast reconstruction trial show stem and regenerative
cell-enriched fat grafting resulted in a high sustained rate of physician and
patient satisfaction and persistent improvements in overall outcomes of the
procedure at six and 12 months.
Improvements in outcomes previously reported in 30 patients at six months
were confirmed in a larger sample of 51 patients at six months. These
improvements were sustained for the first 30 patients to reach the 12-month
evaluation period.
The European trial, referred to as RESTORE 2, is sponsored by Cytori
Therapeutics (NASDAQ: CYTX) and enrolled a total of 71 patients. The fat grafts
in the study were enriched with stem and regenerative cells using Cytori's
European-approved Celution(R) 800 System. The interim data reported today was
presented at the Fifth Winchester-Jersey Masterclass in Oncoplastic Breast
Surgery at the Royal Hampshire County Hospital.
Interim results from the RESTORE 2 trial demonstrated a high rate of
physician and patient satisfaction at six and 12 months:
-- Overall physician satisfaction with treatment results was 84% at six
months in 51 patients
-- Overall physician satisfaction with treatment results (90%) persisted in
the first 30 patients at 12 months
-- Overall patient satisfaction with treatment results was 73% in 51
patients measured at six months
-- Overall patient satisfaction with treatment results (70%) persisted in
the 30 patients at 12 months
"Medical research has found that untreated partial mastectomy defects
negatively affects patients' psychology and quality of life1," said Dr. Eva
Weiler-Mithoff, M.D., co-principal investigator for RESTORE 2 at the Glasgow
Royal Infirmary. "With reconstruction, patients are less likely to feel
depressed or stigmatized and more likely to appreciate the treatment of breast
cancer."
"A woman is not cured until she is reconstructed. Unfortunately for most
patients, few options are available and there is currently no accepted
standard-of-care for breast reconstruction," added Dr. Rosa Perez Cano,
co-principal investigator for RESTORE 2 and Chief of Plastic Surgery Services
at Hospital Universitario Gregorio Maranon, Madrid, Spain. "These interim
results are encouraging as we see consistent improvements in breast deformity,
breast symmetry and tissue elasticity."
Cell-enriched breast reconstruction is a new procedure that addresses the
unmet need created by partial mastectomy. This approach uses a woman's own fat
tissue combined with her own naturally available adipose-derived stem and
regenerative cells to form a 'cell-enriched' fat graft, which is used to
reconstruct the affected breast.
In RESTORE 2, the cell-enriched graft was prepared by first extracting each
patient's own stem and regenerative cells from their fat tissue using Cytori's
Celution(R) 800/CRS System and then combining these cells with the fat graft,
all in the same surgical procedure. More information on cell-enriched breast
reconstruction and other reconstructive surgery options for breast cancer is
available at www.cellreconstruct.eu.
RESTORE 2 is a post-marketing study primarily intended to measure physician
and patient satisfaction in reconstructing the breast utilizing the Celution
800/CRS System. The study endpoints have been designed, among other things, to
address hospital and physician reimbursement and adoption of the Celution(R)
800/CRS System throughout Europe. The outcomes of the study will be assessed at
12 months, per study design.
For more information, log on to www.cytori.com.
1 "Effect of Esthetic Outcome After Breast-Conserving Surgery on Psychosocial
Functioning and Quality of Life" Journ. Of Clin. Oncology Vol 26 No. Jul 2008
About Cytori
Cytori is a leader in providing patients and physicians around the world with
medical technologies that harness the potential of adult regenerative cells
from adipose tissue. The Celution(R) System family of medical devices and
instruments is being sold into the European and Asian cosmetic and
reconstructive surgery markets but is not yet available in the United States.
Our StemSource(R) product line is sold globally for cell banking and research
applications. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements are subject to risks and uncertainties
that could cause our actual results and financial position to differ
materially. Some of these risks include clinical and regulatory uncertainties,
including risks in the collection and results of clinical data, final clinical
outcomes, dependence on third party performance, and other risks and
uncertainties described under the "Risk Factors" in Cytori's Securities and
Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no
responsibility to update or revise any forward-looking statements to reflect
events, trends or circumstances after the date they are made.
CONTACT: Media Contact:
RLM Public Relations for Cytori
Sharon Nieuwenhuis,
212-741-5106 x237
cytori@RLMpr.com
or
Investor Contact:
Cytori
Tom Baker
858-232-7234
tbaker@cytori.com
SOURCE: Cytori Therapeutics
Copyright Business Wire 2010
Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=fK3OT%2BzzxHMGA2%2BJkQ4xgQ%3D%3D. You can
use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
06-17-10 1125ET
11:25 061710
Yes, there is a pending clearance,but I would not count on that happening this month.Clearances have been behind.As far as PPS,right now BIEL is bullish.
BIEL News...BioElectronics Announces New Product Offerings and Enhancements to Target the
Japanese Marketplace
FREDERICK, MD, Jun 17, 2010 (MARKETWIRE via COMTEX) -- BioElectronics Corporation
(PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free
anti-inflammatory devices, and YesDTC Holdings (YESD), BioElectronics' exclusive
distributor in Japan, today announced several important product line enhancements
specifically tailored to suit the needs of the highly discerning and
quality-conscious Japanese marketplace. These enhancements include requested
modifications to the Allay(TM) Menstrual Pain Therapy and ActiPatch(TM) brands of
products. Additionally, upon release, BioElectronics will make the recently
announced back pain belt available first to the Japanese marketplace.
"We are very excited about our prospects within the Japanese market as both its
medical practitioners and consumers are typically highly accepting of new
treatment therapies. This, combined with the robustness of the economy and the
favorable regulatory climate, leads us to believe Japan could easily be one of
the most robust markets for our drug-free, anti-inflammatory and pain relieving
technologies," commented Georgianna Golematis, Allay Brand Manager at
BioElectronics. "We are excited to begin offering these product enhancements and
to soon offer this new product to the Japanese marketplace."
Enhancements to the Allay product line will include a significantly improved
on/off switch that will allow women to easily preserve battery life to enable use
of the product for at least 10 menstrual cycles. Additionally, based on feedback
from BioElectronics' Japanese distribution partners, several other important
hygienic and aesthetic features of the product are being modified to better fit
the Japanese marketplace. The ActiPatch product will also see modifications,
which will include the fitting of new and stronger, flexible and breathable
fabrics to ensure better fit and comfort.
Management of BioElectronics recently announced a revolutionary back pain belt,
specifically designed to offer a safer alternative therapy for the approximately
80% of adults who suffer from this ailment. Due to favorable Japanese regulatory
environment, combined with the sheer size of the Japanese economy, BioElectronics
has agreed with its Japanese distribution partner to use Japan as one of its test
beds for not only these new devices, but also for the enhanced Allay and
ActiPatch product offerings.
About BioElectronics Corporation BioElectronics Corporation (PINKSHEETS: BIEL) is
the maker of safe, inexpensive, drug-free medical devices and patches that
deliver pulsed electromagnetic energy to relieve pain and inflammation. The
company's wafer thin patches contain an embedded microchip and battery that
deliver pulsed electromagnetic energy, a clinically proven and widely accepted
anti-inflammatory and pain relief therapy that heretofore has only been possible
to obtain from large, facility-based equipment. BioElectronics markets and sells
its current products under the brand names ActiPatch(R), RecoveryRx(TM),
Allay(TM) Menstrual Pain Therapy and HealFast(TM) Therapy for cats, dogs and
horses. The company is headquartered in Frederick, MD. For more information,
visit http://www.bielcorp.com.
BIEL is running on some fantastic updated news that was announced this week.
POSC will jump as soon as it announces its partnership.Which should happen soon.
As far as production, another scheduled run will happen the end of this month.
TDLP News..Transdel Pharmaceuticals Enters into License Agreement with Jan Marini Skin
Research for Cosmeceutical Product
Agreement Includes Exclusive U.S. License to Transdel's Delivery Technology for
Use in an Anti-Cellulite Cosmeceutical Product
LA JOLLA, Calif., June 17, 2010 /PRNewswire via COMTEX/ -- Transdel
Pharmaceuticals, Inc. (TDLP) ("Transdel") and Jan Marini Skin Research, Inc.
("JMSR") have entered into a licensing agreement providing JMSR with the
exclusive U.S. rights to Transdel's transdermal delivery technology for use in an
anti-cellulite cosmeceutical product for the dermatological market.
Under the terms of the agreement, JMSR will pay Transdel a licensing royalty on
the U.S. and worldwide sales of an anti-cellulite product using Trandel's
delivery technology. JMSR obtained an exclusive right to promote and sell a
product in the U.S. dermatological market for approximately one-year after which
time they have a non-exclusive right. Also, JMSR obtained a non-exclusive right
to promote and sell the product in the ex-U.S. dermatological market.
"We are very excited with the establishment of our relationship with JMSR and
look forward to building on this relationship in order to potentially launch
additional cosmeceutical products," stated John Lomoro, Acting Chief Executive
Officer and Chief Financial Officer. "They are a recognized leader in the
dermatological market, so we are confident they will fully capitalize on the
potential for this anti-cellulite technology."
"We believe that Transdel's anti-cellulite technology has the potential to
provide us with an excellent opportunity in the dermatological market not only in
the U.S. but also for the international market," stated Jan Marini, JMSR's
President and Chief Executive Officer. "We look forward to collaborating with
Transdel on this project and potentially other product opportunities."
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (TDLP) is a specialty pharmaceutical company
developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the tough
skin barrier. Ketotransdel(R), the Company's lead pain product, has completed a
Phase 3 clinical trial and utilizes the Transdel(TM) technology to deliver the
active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin
directly into the underlying tissues where the drug exerts its well-known
anti-inflammatory and analgesic effects. The Company intends to leverage its
Transdel(TM) platform technology to expand and create a portfolio of topical
products for a variety of indications. The Company is actively pursuing
partnerships with companies to expand its product portfolio for pharmaceutical
and cosmetic/cosmeceutical products. For more information, please visit
http://www.transdelpharma.com.
About Jan Marini Skin Research, Inc.
San Jose, CA-based Jan Marini Skin Research, Inc. ("JMSR") is a recognized leader
and innovator in skin care, providing state-of-the-art technologies and
breakthroughs in medically based skin care therapies. The JMSR Skin Care
Management Center is used and trusted by physicians and skin care professionals
worldwide to ensure optimum results for their patients and clients.
Safe Harbor Statement
The Company cautions you that the statements included in this press release that
are not a description of historical facts are forward-looking statements. These
include statements regarding: the Company's interpretation of the results of its
Phase 3 clinical trial for Ketotransdel(R); the Company's ability to obtain
regulatory approval to market Ketotransdel; and the Company's ability to complete
additional development activities for products utilizing its proprietary
transdermal delivery platform. Actual results may differ materially from those
set forth in this press release due to the risks and uncertainties inherent in
the Company's business, including, without limitation: the outcome of the final
analyses of the data from the Phase 3 clinical trial may vary from the Company's
initial conclusions; the FDA may not agree with the Company's interpretation of
such results or may challenge the adequacy of the Company's clinical trial design
or the execution of the clinical trial; the FDA may continue to require the
Company to complete additional clinical trials for Ketotransdel(R) before the
Company can submit a 505(b)(2) NDA application; the results of any future
clinical trials may not be favorable and the Company may never receive regulatory
approval for Ketotransdel(R); and the Company's current need to raise additional
funding to complete its product development plans. More detailed information
about the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read
free of charge on the SEC's web site at http://www.sec.gov. You are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.
SOURCE Transdel Pharmaceuticals, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
Kngm,I am sorry, I cannot give you financial advice,everyone has a different financial situation and risk tolerance.
Kngm,guessing PPS is like fortune telling,which I do not have the ability to do.I don't want to mislead anyone with guesses. I do want to share my DD. That is where the the best decisions are made.I personally am comfortable with my investment of EVRN and will be adding.But,please follow your own road of risk tolerance.
I have confirmed that the Whole Foods order was shipped and arrived at the distributor.Should be on shelves today.Let see some sales!!
I promise I will have some pictures of the show and Natures Peak up soon,unfortunately I am in some of them.LOL
Thanks,Pennystalker
You are right any quality company takes time,but the new marketing company is near complete and the aggressive promotion of Natures Peak is happening now.Things are picking up fast.As a point of clarification of company structure... Robert is the heart and soul of the business aspects of Nature Peak ( Financing,moving the company out of the pinks etc.)Robert also is the lead man on putting the marketing company together. Paul is the front line man,working on increase sales,working the shows,on-line ordering,working with source one on strategies and other business aspects of Natures Peak.
Tom and Bob are managing partners of Source One.These boys are pros in their field.
With this marriage of talent pooled together makes for a very powerful team in the food industry.
Thanks...KngmAZ,
I never predict PPS.What I can tell you is the way Natures Peak is shaping up and the forming of the new marketing entity to promote it and assist in financing their product to market, we have a great investment.This company is absolutely no pump and dump.But please remember,in any start up there is risk.
Sorry guys about the delay I have been slammed(in a good way) in my business.What I suggest, since I have a lot of information,is to ask me any questions you may have and I will answer them promptly.
Here is a little information...I was able to get in to the Kehe Holiday Show in Chicago which ran June 13th to the 15th.This is a very big show featuring hundreds of food vendors,brokers and dealers. I went on the last day,as I was immediately greeted by Paul and brought over to the Natures Peak booth. It was a professional set up with the Natures Peak banner in back and a table set up in front with all the flavors set it. There were veggies and meats for sampling.I tried all the flavors on a sandwich and veggies,they were amazing.As I was there,which was about 5 hours, I was talking to Paul,about everything,but then left him alone coming back time to time.I observed Paul as he was working the crowd of dealers like a pro,bring them to the sampling table.The over-all response from the small independent retailers and multi-store dealers was extremely positive. I was right there as Paul was writing orders right in front of me.I can tell you right now,Paul is extremely passionate in what he is doing,a matter of fact,at the Saturday night Kehe dealer party he hung out with the Whole Food regional and national managers working on the relationship with them, which went well.
I also, had the opportunity to meet Tom and Bob of Source One,in which we discussed new company and the marketing strategy of Natures Peak. These guys are absolute veterans in the business,they knew almost all the dealers at the show.What I can tell you is the marketing strategy is extremely aggressive.
I learned that this business is all about relationships with the dealers and brokers and Natures Peak has gained huge ground in that front,and with Source One promoting Natures Peak now stronger than ever,should really propel the Natures Peak product line.A matter of fact Tom was meeting with Stop and Shop stores this week and will be heavily promoting Natures Peak.
Thats all the time I have for now, but please ask me your questions..I am right there in the trenches with you all,that is why I went to the show....to get the real answers.
Have a great day!
The is huge news for BIEL!
It was amazing. I tried all the flavors,Paul gave me a full sandwich with the veggie spread (Cilantro/lime) on it which was fantastic. Also tried different veggies in the dip which was also great.The dips and spreads had a very smooth mayo texture.Everyone that came to the booth loved the product and I witnessed many orders being placed by individual stores as well as multi-store companies.
I will report more soon.
Just came back from the Kehe Food Show in Chicago..I spent a lot of time with Paul of Natures Peak and Tom and Bob from Source one..Great show with a lot of sales.I will give you my full report soon.I also will be able to share pictures of Natures Peak booth and product display I took.I am very pumped.
AEMD News..Aethlon Medical Releases Shareholder Letter to Discuss Cancer Exosome Studies in
The U.S.
SAN DIEGO, June 15, 2010 /PRNewswire via COMTEX/ -- Aethlon Medical, Inc. (AEMD),
the pioneer in developing therapeutic filtration devices to address infectious
disease and cancer, disclosed today that its Chairman and CEO, James A. Joyce has
issued the following letter to shareholders.
(Logo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
Dear Shareholder:
Should you or a loved one become afflicted with cancer, tumors will release
particles that kill off immune cells needed to combat cancer. We recently
discovered our Hemopurifier(R) is effective in capturing these particles, known
as exosomes. Prior to this observation, a therapeutic strategy to directly
inhibit or remove this immunosuppressive mechanism did not exist in cancer care.
On May 4th of this year, we disclosed our intent to utilize relationships in
India to initiate a human pilot study to clinically document the effect of
removing tumor-secreted exosomes on the immune response of cancer patients. Since
revealing our plan, we have received an overwhelming number of collaborative
inquiries from leading cancer research centers worldwide. As a result, we
reevaluated our clinical strategy and have decided to pursue our first
opportunity to treat cancer in the United States. However, we will continue to
monitor treatment opportunities in other regions. While there is no assurance of
success, feedback from thought leaders in the oncology field indicates that we
are positioned at the forefront of the emerging industry to address cancer
related exosomes. As you can imagine, we are thrilled to be able to leverage the
same Hemopurifier(R) we actively advance in infectious disease as a cancer
treatment candidate. Regarding our infectious disease opportunities, please note
that we have reached an agreement on the protocol of our upcoming Hepatitis-C
virus (HCV) treatment program in India, which will be detailed in a forthcoming
report. I thank you for your continued support and belief in our endeavors, which
has been instrumental in allowing us to advance our cancer discovery.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements in the above Shareholder Letter may be forward-looking
and involve risks and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Aethlon Medical, Inc. to
be materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the capability of the Hemopurifier(R)
to reduce viral loads and other disease conditions or to identify disease
conditions such as cancer, including the ability to capture exosomes and the
impact that potential ability may have on disease conditions, the Company's
ability to raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to obtain FDA and
other regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications and Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
The Kehe food show is going on in Chicago now. I may be going.